免疫球蛋白（人）皮下注射 IMMUNOGLOBULIN HUMAN SUB Q 商标名HIZENTRA 参比制剂，美国产品，一次性进价，平价供应
英文名：IMMUNOGLOBULIN HUMAN SUB Q
商标名：HIZENTRA
中文名：免疫球蛋白（人）皮下注射
生产商：CSL BEHRING AG
剂 型：注射剂
上市国家：
包装规格[注：本品不供病人]
HIZENTRA 10GM SDV 50ML 1/EA $2,140.00 IMMUNOGLOBULIN HUMAN SUB Q CSL BEHRING AG 44206-0455-10
HIZENTRA 1GM SDV 5ML 1/EA $868.92 IMMUNOGLOBULIN HUMAN SUB Q CSL BEHRING AG 44206-0451-01
HIZENTRA 2GM SDV 10ML 1/EA $1028.42 IMMUNOGLOBULIN HUMAN SUB Q CSL BEHRING AG 44206-0452-02
HIZENTRA 4GM SDV 20ML 1/EA $1248.00 IMMUNOGLOBULIN HUMAN SUB Q CSL BEHRING AG 44206-0454-04
-----------------------------------------
Hizentra（Immune Globulin Subcutaneous (Human) (IGSC)] 20% Liquid for Injection）
HIZENTRA Rx
Generic Name and Formulations:
Immune globulin (human) 0.2g/mL (20%); liq for SC infusion; contains L-proline, polysorbate-80; preservative-, and sucrose-free.
Company:
CSL Behring, LLC
Indications for HIZENTRA:
As replacement therapy for primary humoral immunodeficiency (eg, congenital or X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies). As maintenance therapy to prevent relapse of neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
Adults and Children:
See full labeling. Individualize. Give by SC infusion using an infusion pump into abdomen, thigh, upper arm, or lateral hip areas. May use up to 8 infusion sites (at least 2 inches apart) simultaneously. Rotate sites. Primary immunodeficiency: <2yrs: not established. Ensure patients have received IGIV at regular intervals for at least 3 months before initiation; obtain serum IgG trough level to guide subsequent dose adjustments. Start 1 week after last IGIV or IGSC infusion (for weekly or frequent dosing), or 1–2 weeks after last IGIV infusion or 1 week after last weekly IGSC infusion (for biweekly dosing). ≥2yrs: initial weekly dose: (1.37 x previous IGIV dose [in grams])/number of weeks between IGIV doses. Infuse as tolerated up to max 15mL per infusion site at max 15mL/hr/site for first dose; may increase to 25mL/site at max 25mL/hr/site for subsequent doses. Biweekly dose: multiply the calculated weekly dose by 2. Frequent dosing (2–7 times/week): divide calculated weekly dose by the desired number of times per week. Switching from IGSC: maintain previous IGSC weekly dose. Risk of measles exposure: give a minimum total weekly dose of 0.2g/kg for 2 consecutive weeks; if biweekly dosing: give one infusion at minimum of 400mg/kg. Dose adjustments: based on serum IgG trough levels after 2–3 months of initiation and desired clinical response (see full labeling). CIDP: <18yrs: not established. Start 1 week after last IGIV infusion. ≥18yrs: 0.2g/kg (1mL/kg) per week in 1–2 sessions over 1–2 consecutive days (0.4g/kg/week was also shown effective in clinical study). Infuse as tolerated up to max 20mL per infusion site at max 20mL/hr/site for first dose; may increase to 50mL/site at max 50mL/hr/site for subsequent doses. If worsening CIDP sy |
